The survival rates of patients with kidney cancer largely depend on identifying biomarkers. The identification of these biomarkers can help determine a course of treatment. A recent study, published in JAMA, compares data from 6 clinical trials and reported in 9 publications. The report examined how biomarkers and other factors may be associated with favorable outcomes.
“Study responses were pooled using a random-effects meta-analytic model to overcome complexities of such subgroup-level analyses within the individual trials studied. Unlike in a fixed-effect model where scientists can assume a common treatment effect across studies, a random-effects model allows for the assumption that treatment effect might vary by trial.” Read more here.
(Source: Cytel, 2021)